US Veterans Administration Autosomal Dominant Polycystic Kidney Disease Cohort: Demographic, Comorbidity, and Key Laboratory Data Characteristics

被引:0
|
作者
Gallini, Julia W. [1 ]
Jasien, Christine L. [2 ]
Mrug, Michal [3 ,4 ]
Cui, Xiangqin [2 ,5 ]
机构
[1] Fdn Atlanta Vet Educ & Res, Decatur, Georgia
[2] Atlanta VA Hlth Care Syst, Dept Vet Affairs Med Ctr, Decatur, 30033, Georgia
[3] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA
[4] Dept Vet Affairs Med Ctr, Birmingham, AL 35233 USA
[5] Emory Univ, Rollins Sch Publ Hlth, Dept Biostat & Bioinformat, Atlanta, GA 30322 USA
来源
KIDNEY360 | 2024年 / 5卷 / 04期
关键词
ADPKD; CKD; cystic kidney; dialysis; ESKD; PREVALENCE; OUTCOMES; RISK; DEPRESSION; CONSORTIUM; EQUATION;
D O I
10.34067/KID.0000000000000405
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background We used the largest integrated US healthcare system, the Veterans Health Administration, to establish a robust resource for demographic, longitudinal outcome, and predictive modeling studies in autosomal dominant polycystic kidney disease (ADPKD). Methods We built the ADPKD cohort by extracting the relevant electronic health record data from nationwide Veterans Health Administration database (years 1999-2020). Results We identified 12,217 patients diagnosed with ADPKD. By the end of the 20-year study period, 5342 patients with ADPKD were deceased, 1583 were alive but reached ESKD, and 4827 remained alive without ESKD. Most demographic characteristics of this ADPKD cohort resemble the total US veteran population. For example, 94% were male patients, 45% age 65 years or older, 85% non-Hispanic, and 66% white; however, 19% were Black/African Americans (versus 12% in the general veteran population; a relevant enrichment after considering age and sex distributions between races). The comorbidities overrepresented in the ADPKD cohort include hypertension (89% versus 50%), diabetes (32% versus 22%), depression (40% versus 10%), chronic obstructive pulmonary disease (30% versus 6%), and congestive heart failure (21% versus 1%). By contrast, obesity was underrepresented in veterans with ADPKD (30% versus 41%). Conclusions We established a large electronic medical record-based cohort of ADPKD veterans. Here, we provide initial analysis of its demographic, comorbidity, and key laboratory data.
引用
收藏
页码:529 / 537
页数:9
相关论文
共 39 条
  • [21] Cardiometabolic comorbidities in autosomal dominant polycystic kidney disease: a 16-year retrospective cohort study
    Li-Chi Chen
    Yi-Chi Chu
    Tzongshi Lu
    Hugo Y.-H. Lin
    Ta-Chien Chan
    BMC Nephrology, 24
  • [22] Identification of people with autosomal dominant polycystic kidney disease using routine data: a cross sectional study
    McGovern, Andrew P.
    Jones, Simon
    van Vlymen, Jeremy
    Saggar, Anand K.
    Sandford, Richard
    de Lusignan, Simon
    BMC NEPHROLOGY, 2014, 15
  • [23] Characteristics of Congenital Hepatic Fibrosis in a Large Cohort of Patients With Autosomal Recessive Polycystic Kidney Disease
    Gunay-Aygun, Meral
    Font-Montgomery, Esperanza
    Lukose, Linda
    Gerstein, Maya Tuchman
    Piwnica-Worms, Katie
    Choyke, Peter
    Daryanani, Kailash T.
    Turkbey, Baris
    Fischer, Roxanne
    Bernardini, Isa
    Sincan, Murat
    Zhao, Xiongce
    Sandler, Netanya G.
    Roque, Annelys
    Douek, Daniel C.
    Graf, Jennifer
    Huizing, Marjan
    Bryant, Joy C.
    Mohan, Parvathi
    Gahl, William A.
    Heller, Theo
    GASTROENTEROLOGY, 2013, 144 (01) : 112 - U218
  • [24] Leukopenia in autosomal dominant polycystic kidney disease: a single-center cohort of kidney transplant candidates with post-transplantation follow-up
    Schellekens, Pieter
    Van Loon, Elisabet
    Coemans, Maarten
    Meyts, Isabelle
    Vennekens, Rudi
    Kuypers, Dirk
    Mekahli, Djalila
    Bammens, Bert
    CLINICAL KIDNEY JOURNAL, 2023, 16 (12) : 2578 - 2586
  • [25] Copeptin in autosomal dominant polycystic kidney disease: real-world experiences from a large prospective cohort study
    Arjune, Sita
    Oehm, Simon
    Todorova, Polina
    Gansevoort, Ron T.
    Bakker, Stephan J. L.
    Erger, Florian
    Benzing, Thomas
    Burst, Volker
    Grundmann, Franziska
    Antczak, Philipp
    Mueller, Roman-Ulrich
    CLINICAL KIDNEY JOURNAL, 2023, 16 (11) : 2194 - 2204
  • [26] Persistence of tolvaptan medication for autosomal dominant polycystic kidney disease: A retrospective cohort study using Shizuoka Kokuho Database
    Saito, Ryuta
    Yamamoto, Hiroyuki
    Ichihara, Nao
    Kumamaru, Hiraku
    Nishimura, Shiori
    Shimada, Koki
    Mori, Kiyoshi
    Miyachi, Yoshiki
    Miyata, Hiroaki
    MEDICINE, 2022, 101 (40) : E30923
  • [27] Clinical characteristics of patients with autosomal dominant polycystic kidney disease and risk factors for kidney function decline: a single-center study
    Masato Minami
    Shiroh Tanoue
    Takumi Ejima
    Tsubasa Uruta
    Satomi Ichida
    Hidehito Nakamura
    Masayuki Otsuka
    Takahiro Arima
    Rei Obo
    Yawara Yamashita
    Haruhito Yoshimine
    Masaharu Abe
    Yozo Yoshimine
    Masahide Furusho
    Eiji Saeki
    Shuji Kanmura
    Akio Ido
    Renal Replacement Therapy, 11 (1)
  • [28] Characteristics and Distribution of Intracranial Aneurysms in Patients with Autosomal Dominant Polycystic Kidney Disease Compared with the General Population: A Meta-Analysis
    Haemmerli, Julien
    Morel, Sandrine
    Georges, Marc
    Haidar, Fadi
    Chebib, Fouad T.
    Morita, Akio
    Nozaki, Kazuhiko
    Tominaga, Teiji
    Bervitskiy, Anatoliy V.
    Rzaev, Jamil
    Schaller, Karl
    Bijlenga, Philippe
    KIDNEY360, 2023, 4 (04): : E466 - E475
  • [29] Curcumin therapy to treat vascular dysfunction in children and young adults with autosomal dominant polycystic kidney disease: Design and baseline characteristics of participants
    Nowak, Kristen L.
    Farmer-Bailey, Heather
    Cadnapaphornchai, Melissa A.
    You, Zhiying
    George, Diana
    Wang, Wei
    Jovanovich, Anna
    Soranno, Danielle E.
    Gitomer, Berenice
    Chonchol, Michel
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2020, 19
  • [30] Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival-an analysis of data from the ERA-EDTA Registry
    Spithoven, Edwin M.
    Kramer, Anneke
    Meijer, Esther
    Orskov, Bjarne
    Wanner, Christoph
    Abad, Jose M.
    Areste, Nuria
    Alonso de la Torre, Ramon
    Caskey, Fergus
    Couchoud, Cecile
    Finne, Patrik
    Heaf, James
    Hoitsma, Andries
    de Meester, Johan
    Pascual, Julio
    Postorino, Maurizio
    Ravani, Pietro
    Zurriaga, Oscar
    Jager, Kitty J.
    Gansevoort, Ron T.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 : 15 - 25